
| ● |
What does this mean for employees?
|
| ● |
While we are announcing this news today, it is only the first step in the process to bring our companies together.
|
| ● |
We expect to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.
|
| ● |
Until then, Amicus and BioMarin remain two, separate companies, and we will operate largely as usual.
|
| ● |
The vast majority of our work – including supplying our medicines to patients, patient support programs, clinical trial operations, engaging with regulatory agencies and health care providers –
will continue as they normally would. Our patients are counting on us.
|
| ● |
What are BioMarin’s plans for integrating the two companies? When will that begin? Will there be changes to Amicus’ employee base? Job reductions?
|
| ● |
While we are announcing this news today, it is only the first step in the process to bring our companies together.
|
| ● |
We expect to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.
|
| ● |
Over the coming months, dedicated teams from Amicus and BioMarin will be planning on how best to bring our companies together.
|
| ● |
No decisions have been made about the pace or timing of integration.
|
| ● |
We will provide more information once the teams at both our companies have the opportunity to meet and discuss.
|
| ● |
Our highest priorities in this process are to continue our companies’ respective momentum, support patients and the rare disease community, and support our employees.
|
| ● |
Will there be changes to benefits programs for Amicus employees as a result?
|
| ● |
We do not anticipate any changes to Amicus benefits at this time. If there are any changes to benefit programs post integration, that will be communicated at that time.
|

| ● |
Will we get our 2025 bonus, merit increases and stock awards in early January 2026? What is the 2025 bonus corporate multiplier?
|
| ● |
You will be eligible to receive your 2025 bonus based on your individual performance rating and with
an approved Corporate Modifier of 140%. If you were otherwise eligible for a 2026 merit increase, the transaction will not impact that eligibility, and you will receive your 2026 merit increase as would normally happen. Any new salary
will be communicated once compensation changes have been approved. In lieu of a 2026 equity grant you will receive a cash award valued at 25% of what your equity grant value would have been. You will receive this cash value at or promptly
following closing, contingent on your continued employment through that date.
|
| ● |
If I have annual leave booked, do I need to cancel it? If I have planned medical leave, do I need to cancel it?
|
| ● |
No, you should keep your current plans, as long as they have been approved by your manager.
|
| ● |
Will annual planned promotions still take place?
|
| ● |
Approved promotions for January 2026 will proceed.
|
| ● |
Will the Company move forward with hiring plans?
|
| ● |
Most hiring will be paused with the exception of certain roles.
|
| ● |
Should employees expect changes to Amicus’ operating locations, facilities? What about the Company’s Princeton, Marlow, Philadelphia, and affiliate offices?
|
| ● |
No decisions have been made about specific facilities. We will share more information as soon as we have it.
|
| ● |
Will employees have the option to move to California with BioMarin Pharmaceutical?
|
| ● |
While we are announcing this news today, it is only the first step in the process to bring our companies together.
|
| ● |
Over the coming months, dedicated teams from Amicus and BioMarin will be planning on how best to bring our companies together, including whether there are options for employees to move to
BioMarin’s headquarters in California.
|
| ● |
We will provide more information once the teams at both our companies have the opportunity to meet and discuss.
|

| ● |
Will title or job duties change after close? Will there be changes in reporting relationships as a result?
|
| ● |
We expect decisions on titles and job duties after closing to be made as part of the integration planning process led by BioMarin, and we will provide more information once the teams at both our
companies have the opportunity to meet and discuss.
|
| ● |
Can employees buy and sell stock between now and close?
|
| ● |
Until close, Amicus’ stock will continue to trade on the public market NASDAQ just as it does today, and employees can continue to make investment and trading decisions subject to our existing
policies and regulations, including our insider trading policy and any blackout dates. Trading in BioMarin stock will be prohibited during this time unless otherwise indicated by the legal department.
|
| ● |
If you are involved in integration planning or otherwise have questions about whether you can trade under applicable securities laws or our insider trading policy, please contact Christian Formica
at cformica@amicusrx.com or Ellen Rosenberg at erosenberg@amicusrx.com with questions prior to taking any action.
|
| ● |
What happens to stock options employees were granted as part of their equity compensation?
|
| ● |
All outstanding options (vested or unvested) will be cashed out at closing, provided that the strike price of the options is lower than the transaction price.
|
| ● |
The cash payment for any outstanding options will be calculated by deducting the strike price from the transaction price multiplied by the number of options. Applicable taxes will also be deducted
from the income, and the value will be paid to you via payroll.
|
| ● |
Any options with strike prices equal to or above the closing price will be cancelled for no value.
|
| ● |
What happens to restricted stock units (RSUs)?
|
| ● |
Amicus equity will continue to vest under vesting schedules in place until the deal officially closes.
|
| ● |
Unvested RSUs will accelerate and will be cancelled and cashed out at closing based on the transaction price, which will be paid to employees via payroll (less applicable taxes).
|

| ● |
What happens to any shares I have from vested equity awards?
|
| ● |
All Amicus shares will be cashed out at closing. Cash payments will be made by the broker that holds the shares (e.g. Morgan Stanley, E*TRADE).
|
| ● |
What will happen to the Amicus name?
|
| ● |
That will be determined through the integration process led by BioMarin.
|
| ● |
What will happen to the Galafold and Pombiliti + Opfolda brand names?
|
| ● |
We do not expect changes to the Galafold and Pombiliti + Opfolda brand names.
|
| ● |
How do the cultures of the two companies compare?
|
| ● |
There is a lot of overlap in our mission and values. Like Amicus, BioMarin is a company that has been profoundly dedicated to transforming care for patients with rare diseases since its founding.
|
| ● |
In addition to sharing our commitment to transforming care for patients with rare diseases, they believe in building value for all stakeholders and fostering teamwork and respect for each
individual’s contributions.
|
| ● |
Will employees be eligible for severance if they experience a termination of employment following the closing?
|
| ● |
The terms of the U.S. change in control severance plan and all CIC addenda in international employment contracts will be honored. Those terms will be provided to all employees
in the coming weeks.
|
| ● |
Can employees engage on social media about the news?
|
| ● |
As a public company, there are strict SEC rules that determine what and how we are able to share information on social media about today’s announcement.
|
| ● |
U.S. employees: you can “Like” and/or “Repost” -- without comment -- the Amicus LinkedIn post regarding the acquisition. You cannot like,
comment or repost/share third-party social media posts about today’s announcement, and you cannot create your own new post or add any information along with a repost about the news.
|
| ● |
International employees: you cannot “Like”, “Comment” or “Repost” today’s Amicus LinkedIn post regarding the acquisition because it links to our website, which is against our global social media policy. You also
cannot like, comment or repost/share third-party social media posts about today’s announcement.
|

| ● |
What do employees do if contacted by the press, financial analysts or investors?
|
| ● |
Consistent with Company policy, all media inquiries should be forwarded to Brendan McEvoy at bmcevoy@amicusrx.com.
|
| ● |
All financial analyst and investor inquiries should be forwarded to Andrew Faughnan at afaughnan@amicusrx.com.
|

